Monopar Therapeutics (NASDAQ:MNPR) Trading 10.2% Higher

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) shot up 10.2% on Friday . The company traded as high as $0.76 and last traded at $0.73. 129,520 shares were traded during trading, a decline of 97% from the average session volume of 3,984,959 shares. The stock had previously closed at $0.66.

Analysts Set New Price Targets

Separately, Jonestrading upgraded shares of Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Thursday, April 11th.

Monopar Therapeutics Price Performance

The firm has a market cap of $12.69 million, a P/E ratio of -1.19 and a beta of 1.17. The firm’s 50-day moving average price is $0.76 and its 200 day moving average price is $0.52.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. Analysts forecast that Monopar Therapeutics Inc. will post -0.67 earnings per share for the current year.

Institutional Trading of Monopar Therapeutics

A hedge fund recently bought a new stake in Monopar Therapeutics stock. Windsor Advisory Group LLC bought a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 89,974 shares of the company’s stock, valued at approximately $56,000. Windsor Advisory Group LLC owned about 0.64% of Monopar Therapeutics at the end of the most recent quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.